Circulating cell-free tumor DNA analysis of 50 genes by next-generation sequencing in the prospective MOSCATO trial

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 2960-2968

  Jovelet, Cécile ^a   Ileana, Ecaterina ^a,b   Le Deley, Marie Cécile ^c,d,e   Motté, Nelly ^a   Rosellini, Silvia ^c   Romero, Alfredo ^a   Lefebvre, Celine ^f   Pedrero, Marion ^f   Pata Merci, Noémie ^a   Droin, Nathalie ^a   Deloger, Marc ^a   Massard, Christophe ^b   Hollebecque, Antoine ^b   Ferté, Charles ^g   Boichard, Amélie ^a   Postel Vinay, Sophie ^b,f   Ngo Camus, Maud ^b   De Baere, Thierry ^h   Vielh, Philippe ⁱ   Scoazec, Jean Yves ^a,e,i   Vassal, Gilles ^j   Eggermont, Alexander ^e,g   André, Fabrice ^e,f,g   Soria, Jean Charles ^b,e,f   Lacroix, Ludovic ^a,e,f,i   more..

^a CNRS UMS3655   (France)

^b Département d'Innovation Thérapeutique et d'Essais Précoces DITEP   (France)

^c Gustave Roussy   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Gustave Roussy Cancer Campus   (France)

^h Service de Radiologie   (France)

ⁱ Gustave Roussy   (France)

^j Direction de la Recherche Clinique   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APC PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; SMAD4 PROTEIN; CIRCULATING TUMOR DNA; TUMOR MARKER;

ADULT; AGED; AKT1 GENE; APC GENE; ARTICLE; BRAF GENE; BREAST CANCER; CDKN2A GENE; CELL FREE SYSTEM; CONTROLLED STUDY; CTNNB1 GENE; DIGESTIVE SYSTEM CANCER; DNA DETERMINATION; EGFR GENE; ERBB2 GENE; FBXW7 GENE; FEMALE; FEMALE GENITAL TRACT CANCER; GENE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; KIT GENE; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; PIK3CA GENE; PREDICTION; PRIORITY JOURNAL; PTEN GENE; RB1 GENE; SENSITIVITY ANALYSIS; SMAD4 GENE; SOMATIC MUTATION; STK11 GENE; THORAX CANCER; TP53 GENE; TUMOR BIOPSY; URINARY TRACT CANCER; ADOLESCENT; BLOOD; DNA MUTATIONAL ANALYSIS; EVALUATION STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CIRCULATING TUMOR DNA; CLINICAL TRIALS, PHASE I AS TOPIC; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PATIENT SELECTION; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84975047629     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2470     Document Type: Article

References (32)

1. Tursz T, Andre F, Lazar V, Lacroix L, Soria JC. Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 2011;8:177-83.
2. Arnedos M, Vielh P, Soria JC, Andre F. The genetic complexity of common cancers and the promise of personalized medicine: Is there any hope? J Pathol 2014;232:274-82.
3. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin-Oncol 2010;28:4877-83.
4. Wagle N, Berger MF, Davis MJ, Blumenstiel B, De Felice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2012;2:82-93.
5. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014;15:267-74.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumorheterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
7. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
8. Bidard F, Weigelt B, Reis-filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013;5:1-7.
9. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
10. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84.
11. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
12. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013;368:842-51.
13. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
14. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
15. Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015;9:783-90.
16. Ferte C, Massard C, Ileana E, Hollebecque A, Lacroix L, Ammari S, et al.et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Cancer Res 2014;74:CT240.
17. Massard C, Hollebecque A, Rosselini S, Ferté C, Lacroix L, Auger N, et al. Enriching phase I trials with molecular alterations: Interim analysis of 708 patients enrolled in the MOSCATO 01 trial. Ann Oncol 2015;26:ii3-5.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
19. Arkenau H-T, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-6.
20. Akaike H. "A new look at the statistical model identification." IEEE Trans Autom Control 1974;19:716-23.
21. Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: Wiley. 2000. p147-56.
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
23. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224-49.
24. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, et al. Multipurpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012;7:e47020-9.
25. Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (ccfDNA) in blood of cancer patients. Int J Mol Sci 2013;14:18925-58.
26. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136-68.
27. Rothé F, Laes J, Lambrechts D, Smeets D, Vincent D, Maetens M, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014;10:1959-65.
28. Couraud S, VacaPaniagua F, Villar S, Oliver J, Schuster T, Blanche H, et al. Non-invasive diagnosis of actionable mutations by deep sequencing of circulating-free DNA in non-small cell lung cancer: findings from BioCAST/IFCT-1002. Clin Cancer Res 2014;20:4613-24.
29. Frenel J-S, Carreira S, Goodall J, Roda Perez D, Perez Lopez R, Tunariu N, et al. Serial next generation sequencing of circulating cell free DNA evaluating tumour clone response to molecularly targeted drug administration. Clin Cancer Res 2015;21:4586-96.
30. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
31. Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, et al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst 2014;106:1-5.
32. Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C. Computational optimisation of targeted DNA sequencing for cancer detection. Sci Rep 2013;3:3309-18.